NeuroOne Medical Technologies Second Quarter 2025 Earnings: Beats Expectations

NeuroOne Medical Technologies (NASDAQ:NMTC) Second Quarter 2025 Results

Key Financial Results

• Revenue: US$1.39m (flat on 2Q 2024).
• Net loss: US$2.27m (loss narrowed by 21% from 2Q 2024).
• US$0.073 loss per share (improved from US$0.11 loss in 2Q 2024).

Our free stock report includes 4 warning signs investors should be aware of before investing in NeuroOne Medical Technologies. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

NeuroOne Medical Technologies Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 9.2%. Earnings per share (EPS) also surpassed analyst estimates by 22%.

Looking ahead, revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 1.1% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with NeuroOne Medical Technologies (at least 1 which can't be ignored), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.